TR201906318T4 - Tiyenopirimidin türevi üretme yöntemi. - Google Patents

Tiyenopirimidin türevi üretme yöntemi. Download PDF

Info

Publication number
TR201906318T4
TR201906318T4 TR2019/06318T TR201906318T TR201906318T4 TR 201906318 T4 TR201906318 T4 TR 201906318T4 TR 2019/06318 T TR2019/06318 T TR 2019/06318T TR 201906318 T TR201906318 T TR 201906318T TR 201906318 T4 TR201906318 T4 TR 201906318T4
Authority
TR
Turkey
Prior art keywords
producing
salt
thienopyrimidine derivative
provides
present
Prior art date
Application number
TR2019/06318T
Other languages
English (en)
Inventor
Fukuoka Koichiro
Miwa Kazuhiro
Sasaki Tsuyoshi
Komura Fumiya
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TR201906318T4 publication Critical patent/TR201906318T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Mevcut buluş, yüksek verimde yüksek kalitede bir gonadotropin salgılayan hormon (GnRH) antagonistik etkisine sahip bir tiyenopirimidin türevinin veya bunun bir tuzunun üretim yöntemini sağlar. Mevcut buluş, 6-(4-aminofenil)-1-(2,6-diflorobenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)tiyeno[2,3-d]pirimidin-2,4(1H,3H)-dion veya bunun tuzu, 1,1'-karbonildiimidazol veya bunun bir tuzu ve metoksiamin veya bunun bir tuzu ve benzerlerinin reaksiyona girmesini içeren bir tiyenopirimidin türevi üretmeye yönelik bir yöntem sağlar.
TR2019/06318T 2012-09-28 2013-09-27 Tiyenopirimidin türevi üretme yöntemi. TR201906318T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012217679 2012-09-28

Publications (1)

Publication Number Publication Date
TR201906318T4 true TR201906318T4 (tr) 2019-05-21

Family

ID=49448235

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06318T TR201906318T4 (tr) 2012-09-28 2013-09-27 Tiyenopirimidin türevi üretme yöntemi.

Country Status (20)

Country Link
US (8) US9758528B2 (tr)
EP (3) EP2900675B1 (tr)
JP (1) JP6250564B2 (tr)
CN (3) CN104703992B (tr)
AR (1) AR092707A1 (tr)
CA (1) CA2881132C (tr)
CY (1) CY1121641T1 (tr)
DK (2) DK3415517T3 (tr)
ES (2) ES2724206T3 (tr)
HR (2) HRP20220622T1 (tr)
HU (2) HUE059077T2 (tr)
LT (2) LT2900675T (tr)
PL (2) PL3415517T3 (tr)
PT (2) PT2900675T (tr)
RS (2) RS63199B1 (tr)
SI (2) SI2900675T1 (tr)
TR (1) TR201906318T4 (tr)
TW (3) TWI641611B (tr)
UY (1) UY35058A (tr)
WO (1) WO2014051164A2 (tr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2900675T1 (sl) 2012-09-28 2019-06-28 Takeda Pharmaceutical Company Limited Postopek za pridobivanje tienopirimidin derivata
MY180680A (en) 2015-02-26 2020-12-06 Takeda Pharmaceuticals Co Solid preparation
CN110312512B (zh) 2016-09-30 2023-05-09 梦欧文科学有限责任公司 用于治疗子宫肌瘤和子宫内膜异位症的方法
WO2018060463A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
US10787451B2 (en) * 2016-11-14 2020-09-29 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of GnRH receptor antagonist and preparation method therefor
KR20200027481A (ko) 2017-06-05 2020-03-12 옵스에파 에스에이 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법
CN107188855A (zh) * 2017-07-14 2017-09-22 常州工程职业技术学院 一种3‑氨基‑6甲氧基哒嗪的制备方法
US11306104B2 (en) 2018-03-14 2022-04-19 Teva Pharmaceuticals International Gmbh Solid state forms of Relugolix
EP3666776A1 (en) 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
EP3969455A4 (en) * 2019-05-15 2023-07-05 Dr. Reddy's Laboratories Limited AMORPHOUS AND CRYSTALLINE FORMS OF RELUGOLIX
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
EP4004001A4 (en) * 2019-07-29 2023-08-30 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED PYRIMIDINEONE COMPOUNDS AND USES THEREOF
JP2022542159A (ja) * 2019-08-02 2022-09-29 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 固体形態レルゴリクス（Ｒｅｌｕｇｏｌｉｘ）
CN112321602A (zh) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 一种瑞卢戈利药物中间体的制备方法
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
CN112771052B (zh) * 2019-08-21 2023-04-07 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN112745304A (zh) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 一种Relugolix的制备方法及中间体化合物
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN113444105A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种Relugolix的制备方法
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
CN111574534B (zh) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
CN115666531A (zh) 2020-05-29 2023-01-31 梦欧文科学有限责任公司 ***释放激素拮抗剂的组合固体口服剂型
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
JP2023549196A (ja) 2020-11-11 2023-11-22 ミオバント サイエンシズ ゲーエムベーハー レルゴリクスの投与方法
CN112552312B (zh) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN114685468A (zh) * 2020-12-25 2022-07-01 成都硕德药业有限公司 用于治疗子宫肌瘤的药物的中间体化合物及其制备方法
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
CN114907370B (zh) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 高纯度的噻吩并嘧啶化合物及其制备方法
CN115073491A (zh) * 2021-03-12 2022-09-20 上海医药工业研究院 一种瑞卢戈利中间体、其制备方法及其应用
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
CN115594688B (zh) * 2021-06-28 2023-11-17 成都倍特药业股份有限公司 瑞卢戈利中间体的制备方法
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN114230576A (zh) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 一种瑞卢戈利的制备方法
WO2023119333A1 (en) * 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
CN114409629B (zh) * 2022-02-22 2023-12-29 浙江科聚生物医药有限公司 一种高纯度Relugolix关键中间体的制备方法及应用
CN114790189B (zh) * 2022-02-24 2023-06-09 海化生命(厦门)科技有限公司 瑞卢戈利中间体的制备方法
CN114755320A (zh) * 2022-03-17 2022-07-15 南京方生和医药科技有限公司 一种3-氨基-6-甲氧基哒嗪有关物质的检测方法
WO2023194924A1 (en) * 2022-04-08 2023-10-12 Glenmark Life Sciences Limited Process for preparation of relugolix
CN114621249B (zh) * 2022-04-27 2024-01-26 江苏慧聚药业股份有限公司 瑞卢戈利关键中间体的制备
TW202345840A (zh) * 2022-05-05 2023-12-01 台灣神隆股份有限公司 瑞格列克及其中間體的製備方法
CN117285506A (zh) * 2022-07-14 2023-12-26 江西同和药业股份有限公司 一种瑞卢戈利中间体及其制备方法
CN115594689B (zh) * 2022-07-14 2024-03-19 江西同和药业股份有限公司 一种瑞卢戈利中间体、一种瑞卢戈利的合成方法
CN115417883A (zh) * 2022-09-16 2022-12-02 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法
WO2024069492A1 (en) 2022-09-29 2024-04-04 Macfarlan Smith Limited Processes for the preparation and manufacture of relugolix
CN115650950A (zh) * 2022-11-03 2023-01-31 江西同和药业股份有限公司 一种瑞卢戈利中间体及其制备方法以及一种酰胺缩合方法
WO2024126674A1 (en) 2022-12-15 2024-06-20 Medichem, S.A. Process for the preparation of relugolix
CN115650965B (zh) * 2022-12-26 2023-03-31 南京威凯尔生物医药科技有限公司 一种瑞卢戈利关键中间体的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (tr) * 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
JP2859791B2 (ja) * 1992-01-31 1999-02-24 吉富製薬株式会社 ４−ブロモメチルビフェニル化合物の製造法
JPH10298156A (ja) * 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
JP2001316391A (ja) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
AU2001234188A1 (en) 2000-02-29 2001-09-12 Takeda Chemical Industries Ltd. Processes for the production of thienopyrimidine derivatives
GB2361917A (en) * 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002068044A (ja) 2000-09-04 2002-03-08 Yamaha Motor Co Ltd 自動二輪車用ハンドルシート
JP2002088044A (ja) * 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd ４’−ブロモメチル−２−シアノビフェニルの製造方法
ES2252540T3 (es) 2001-09-04 2006-05-16 Akzo Nobel N.V. Tieno (2,3-d) pirimidinas glicino-sustituidas con actividad agonistas combinada lh y fsh.
US7569570B2 (en) * 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
KR20050084311A (ko) 2002-12-20 2005-08-26 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 비디오 이미지 개선 방법 및 이를 이용한 비디오 디코더,셋탑 박스, 텔레비전
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
US7947691B2 (en) * 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
RU2007115517A (ru) 2004-10-25 2008-10-27 Нихон Нохияку Ко. Гербицидная композиция для пастбищно-выпасного хозяйства на холмах и способ борьбы с сорняками
ES2494842T3 (es) * 2005-07-22 2014-09-16 Takeda Pharmaceutical Company Limited Agente que previene la ovulación precoz
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED
CU24177B1 (es) * 2011-02-23 2016-04-25 Lupin Ltd Derivados de heteroarilo como moduladores de nachr alfa 7
JP2012217679A (ja) 2011-04-11 2012-11-12 Okumura Yu-Ki Co Ltd パチンコ遊技機
SI2900675T1 (sl) 2012-09-28 2019-06-28 Takeda Pharmaceutical Company Limited Postopek za pridobivanje tienopirimidin derivata
MY180680A (en) 2015-02-26 2020-12-06 Takeda Pharmaceuticals Co Solid preparation

Also Published As

Publication number Publication date
US20170210753A1 (en) 2017-07-27
PL2900675T3 (pl) 2019-08-30
RS58703B1 (sr) 2019-06-28
TWI663171B (zh) 2019-06-21
RS63199B1 (sr) 2022-06-30
EP3415517A1 (en) 2018-12-19
CN104703992A (zh) 2015-06-10
US20220135585A1 (en) 2022-05-05
WO2014051164A3 (en) 2014-05-22
TWI641611B (zh) 2018-11-21
PT2900675T (pt) 2019-05-28
CN113372358B (zh) 2024-05-14
CN109053766A (zh) 2018-12-21
CN109053766B (zh) 2021-06-22
EP2900675A2 (en) 2015-08-05
US20200361953A1 (en) 2020-11-19
US20180319816A1 (en) 2018-11-08
US10464945B2 (en) 2019-11-05
EP4119564A1 (en) 2023-01-18
JP6250564B2 (ja) 2017-12-20
US20220204525A1 (en) 2022-06-30
EP3415517B1 (en) 2022-04-20
US10150778B2 (en) 2018-12-11
US11795178B2 (en) 2023-10-24
ES2913753T3 (es) 2022-06-06
US11053257B2 (en) 2021-07-06
DK2900675T3 (da) 2019-06-03
ES2724206T3 (es) 2019-09-09
TWI602819B (zh) 2017-10-21
SI2900675T1 (sl) 2019-06-28
LT2900675T (lt) 2019-05-27
WO2014051164A2 (en) 2014-04-03
CN104703992B (zh) 2019-03-05
US20190055261A1 (en) 2019-02-21
DK3415517T3 (da) 2022-05-30
CA2881132A1 (en) 2014-04-03
HRP20220622T1 (hr) 2022-06-24
TW201906847A (zh) 2019-02-16
TW201418262A (zh) 2014-05-16
LT3415517T (lt) 2022-06-10
US11731983B2 (en) 2023-08-22
PT3415517T (pt) 2022-05-13
CA2881132C (en) 2020-11-24
JP2015532262A (ja) 2015-11-09
US10544160B2 (en) 2020-01-28
CY1121641T1 (el) 2020-07-31
UY35058A (es) 2014-04-30
EP2900675B1 (en) 2019-03-06
PL3415517T3 (pl) 2022-07-04
US20150266891A1 (en) 2015-09-24
HRP20190729T1 (hr) 2019-06-14
AR092707A1 (es) 2015-04-29
CN113372358A (zh) 2021-09-10
US20230212184A1 (en) 2023-07-06
TW201808962A (zh) 2018-03-16
US9758528B2 (en) 2017-09-12
HUE059077T2 (hu) 2022-11-28
HUE044048T2 (hu) 2019-09-30
SI3415517T1 (sl) 2022-06-30

Similar Documents

Publication Publication Date Title
TR201906318T4 (tr) Tiyenopirimidin türevi üretme yöntemi.
FR22C1006I2 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
HK1217707A1 (zh) 用於治療病毒性感染的噻吩並 嘧啶衍生物
SI3379933T1 (sl) Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina
RS61319B1 (sr) Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za lečenje kancera
HK1218116A1 (zh) 用於治療病毒感染和其他疾病的吡咯並 嘧啶衍生物
CU24396B1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
IL275624B (en) Optionally converted pyrimidine derivatives in conjugated heterocycles for use in the treatment of inflammatory, metabolic, oncological and autoimmune diseases
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
MX2017001284A (es) Tieno [3,2-d] pirimidina, furo[3,2-d] pirimidina y pirrolo [3,2-d] pirimidinas utiles para el tratamiento de infecciones por virus sincitial respiratorio.
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
SG11201505520WA (en) 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
IN2015DN03751A (tr)
IN2014MN02228A (tr)
IL265923A (en) Modified 6-(h1-pyrazol-1-yl)pyrimidin-4-amine histories and their uses
SI3596080T1 (sl) Farmakološko aktivni aliciklični-substituirani pirazolo-(1,5-a)pirimidinski derivati
WO2015082376A3 (en) Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for the treatment of cancer
PL3438096T3 (pl) Sposób wytwarzania 1-(arylometylo)chinazolino-2,4(1H,3H)-dionu
MX2015003314A (es) Proceso para la preparacion de 2-amino-5,8-dimetoxi[1,2,4]triazol[ 1,5-c] pirimidina a partir de 4-cloro-2,5-dimetoxipirimidina.
UA80383U (en) 7-(1,3-benzothiazole-2-ylthio)-3-methyl-6,7-dihydro-1h-cyclopenta[d]pyrimidine-2,4(3h,5h)-dione
IN2013MU03403A (tr)
LV14663A (lv) Pirolo[1,2-a]hinazolīna atvasinājumu sintēze no N-antranilskābes hidrazīdiem un alfa-ketoskābēm
UA78667U (en) 4,7-dioxo-2-chloromethyl-9-(2-chlorophenyl)-3,4,6,7,8,9-hexahydropyrido[3',2':4,5]thieno[3,2-d]pyrimidine
UA80808U (en) 2-methyl-4,7-dioxo-9-(2-chlorophenyl)-3,4,6,7,8,9-hexahydropyrido[3',2':4,5]-thieno[3,2-d]pyrimidine